Organization
Lund, Sweden
5 abstracts
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Abstract
Age-, sex-, and race-related differences in outcomes of patients with muscle-invasive bladder cancer treated with radical cystectomy: The role of biology versus access to standard medical care.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, Lund University Cancer Center, Lund, Sweden, University of Texas MD Anderson Cancer Center,
Abstract
AN ORALLY AVAILABLE HIGHLY SELECTIVE 5-HYDROXYTRYPTAMINE 2B (5-HT2B) RECEPTOR ANTAGONIST AMELIORATING PULMONARY AND DERMAL FIBROSIS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSISOrg: AnaMar AB, Lund, Medicon Village AB, Lund, Sweden,
Abstract
A LOCUS ON MOUSE CHROMOSOME 5 CONTROLLING TRAITS OF INFLAMMATORY DISEASEOrg: MEDICAL INFLAMMATION RESEARCH, Lund University, Lund, Sweden, Dept. of Pharmacology and Pharmacotherapy, Danish University of Pharmaceutical Sciences,
Abstract
ABR-224050 A NOVEL DIHYDROOROTATE DEHYDROGENASE INHIBITOR SUPPRESSING DISEASE DEVELOPMENT IN COLLAGEN INDUCED ARTHRITIS IN DBA/1 MICEOrg: Research and Development Laboratories, Active Biotech Research AB, Lund, Sweden, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Chelsea Therapeutics,